Bank of New York Mellon
CCCC icon

Bank of New York Mellon’s C4 Therapeutics CCCC Stock Holding History

Bank of New York Mellon’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
+249,517
New +$853K ﹤0.01% 3271
2025
Q2 		– Sell
-141,284
Closed -$226K – 4158
2025
Q1 		$226K Buy
141,284
+201
+0.1% +$600 ﹤0.01% 3834
2024
Q4 		$508K Sell
141,083
-2,210
-2% -$11K ﹤0.01% 3515
2024
Q3 		$817K Sell
143,293
-47,468
-25% -$286K ﹤0.01% 3255
2024
Q2 		$881K Buy
+190,761
New +$1.14M ﹤0.01% 3272
2024
Q1 		– Sell
-20,682
Closed -$117K – 4181
2023
Q4 		$117K Sell
20,682
-189
-0.9% -$431 ﹤0.01% 4061
2023
Q3 		$38.8K Sell
20,871
-1,410
-6% -$4.3K ﹤0.01% 4186
2023
Q2 		$61.3K Sell
22,281
-129,276
-85% -$416K ﹤0.01% 4148
2023
Q1 		$476K Sell
151,557
-945
-0.6% -$5.56K ﹤0.01% 3513
2022
Q4 		$900K Buy
152,502
+666
+0.4% +$5.52K ﹤0.01% 3245
2022
Q3 		$1.33M Buy
151,836
+18,332
+14% +$190K ﹤0.01% 3068
2022
Q2 		$1.01M Buy
133,504
+6,432
+5% +$56.6K ﹤0.01% 3206
2022
Q1 		$3.08M Buy
127,072
+1,601
+1% +$38.9K ﹤0.01% 2691
2021
Q4 		$4.04M Buy
125,471
+12,873
+11% +$509K ﹤0.01% 2581
2021
Q3 		$5.03M Buy
112,598
+28,053
+33% +$1.2M ﹤0.01% 2483
2021
Q2 		$3.2M Buy
84,545
+55,028
+186% +$1.97M ﹤0.01% 2715
2021
Q1 		$1.09M Buy
29,517
+1,176
+4% +$46.8K ﹤0.01% 3279
2020
Q4 		$939K Buy
+28,341
New +$822K ﹤0.01% 3278

Other funds holding CCCC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
VIG
Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

Bank of New York Mellon's CCCC Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 249,517 shares worth $1.17M. The stake represents ﹤0.01% of the portfolio and ranks #3271 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CCCC as recently as Q1 2025.

Bank of New York Mellon first reported a position in CCCC in Q4 2020 and has held it in 18 quarters since. The position peaked at $5.03M in Q3 2021. 41 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Bank of New York Mellon held 249,517 shares of C4 Therapeutics worth $1.17M as of Q2 2026.
  • C4 Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3271 holding.
  • Bank of New York Mellon first reported a position in C4 Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • Bank of New York Mellon's C4 Therapeutics position peaked at $5.03M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.